Safety of left atrial appendage closure in heart failure patients

Left atrial appendage closure (LAAC) is an intervention aimed at stroke prevention in nonvalvular atrial fibrillation (AF). There is a three‐fold increased risk of stroke in patients with concomitant presence of AF and heart failure (HF). While anticoagulation is effective, only 60% receive it. We aimed at studying the safety of LAAC in HF patients using a national all‐payer database.

[1]  S. Virani,et al.  Association of Body Mass Index with Outcomes in Patients Undergoing Percutaneous Left Atrial Appendage Closure with the Watchman Device. , 2021, Current problems in cardiology.

[2]  B. Kantharia,et al.  Safety and complications of catheter ablation for atrial fibrillation: Predictors of complications from an updated analysis the National Inpatient Database , 2021, Journal of cardiovascular electrophysiology.

[3]  Caterina Mas-Lladó,et al.  Effect of Glomerular Filtration Rates on Outcomes Following Percutaneous Left Atrial Appendage Closure. , 2021, The American journal of cardiology.

[4]  G. Lippi,et al.  Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge , 2020, International journal of stroke : official journal of the International Stroke Society.

[5]  M. Kelm,et al.  Kidney function stratified outcomes of percutaneous left atrial appendage occlusion in patients with atrial fibrillation and high bleeding risk , 2020, Acta cardiologica.

[6]  E. Heist,et al.  Incidence and Causes of In-hospital Outcomes and 30-day Readmissions After Percutaneous Left Atrial Appendage Closure: A United States Nationwide Retrospective Cohort Study Using Claims Data. , 2020, Heart rhythm.

[7]  D. Delurgio,et al.  Long-Term Safety and Efficacy in Continued Access Left Atrial Appendage Closure Registries. , 2019, Journal of the American College of Cardiology.

[8]  S. Windecker,et al.  Incidence, predictors, and relevance of acute kidney injury in patients undergoing left atrial appendage closure with Amplatzer occluders: a multicentre observational study , 2019, Clinical Research in Cardiology.

[9]  T. Münzel,et al.  5-Year Experience of In-Hospital Outcomes After Percutaneous Left Atrial Appendage Closure in Germany. , 2019, JACC. Cardiovascular interventions.

[10]  Tanush Gupta,et al.  Intracardiac vs transesophageal echocardiography for percutaneous left atrial appendage occlusion: A meta‐analysis , 2019, Journal of cardiovascular electrophysiology.

[11]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Heart rhythm.

[12]  P. Chan,et al.  Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. , 2017, Journal of the American College of Cardiology.

[13]  C. Morillo,et al.  Early Canadian Multicenter Experience With WATCHMAN for Percutaneous Left Atrial Appendage Closure , 2017, Journal of cardiovascular electrophysiology.

[14]  S. Kische,et al.  Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry , 2016, European heart journal.

[15]  M. Price,et al.  Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. , 2014, Journal of the American College of Cardiology.

[16]  P. Meier,et al.  Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation: an update , 2014, Open Heart.

[17]  S. Jaggar,et al.  General anesthesia versus sedation for implantation of a biventricular pacing device for cardiac resynchronization therapy. , 2014, Journal of cardiothoracic and vascular anesthesia.

[18]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[19]  M. Mador,et al.  Post-operative outcomes in adult obstructive sleep apnea patients undergoing non-upper airway surgery: a systematic review and meta-analysis , 2014, Sleep and Breathing.

[20]  Petr Neuzil,et al.  Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). , 2013, Journal of the American College of Cardiology.

[21]  L. Morrow,et al.  Impact of COPD on postoperative outcomes: results from a national database. , 2013, Chest.

[22]  Saibal Kar,et al.  Safety of Percutaneous Left Atrial Appendage Closure: Results From the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued Access Registry , 2011, Circulation.

[23]  Maurice Buchbinder,et al.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2009, The Lancet.

[24]  C. Wolfe,et al.  Characteristics, Outcome, and Care of Stroke Associated With Atrial Fibrillation in Europe: Data From a Multicenter Multinational Hospital–Based Registry (The European Community Stroke Project) , 2001, Stroke.

[25]  J. Odell,et al.  Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. , 1996, The Annals of thoracic surgery.

[26]  I. Sand.  Predictors of Thromboembolism in Atrial Fibrillation: I. Clinical Features of Patients at Risk , 1992, Annals of Internal Medicine.